- Home
- VWAV vs BDTX Comparison
VWAV vs BDTX Comparison
Compare VWAV & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VWAV
- BDTX
- Stock Information
- Founded
- VWAV 2024
- BDTX 2014
- Country
- VWAV United States
- BDTX United States
- Employees
- VWAV N/A
- BDTX N/A
- Industry
- VWAV Computer Software: Prepackaged Software
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VWAV Technology
- BDTX Health Care
- Exchange
- VWAV Nasdaq
- BDTX Nasdaq
- Market Cap
- VWAV 162.2M
- BDTX 181.4M
- IPO Year
- VWAV N/A
- BDTX 2020
- Fundamental
- Price
- VWAV $13.39
- BDTX $3.89
- Analyst Decision
- VWAV
- BDTX Strong Buy
- Analyst Count
- VWAV 0
- BDTX 5
- Target Price
- VWAV N/A
- BDTX $10.40
- AVG Volume (30 Days)
- VWAV 342.9K
- BDTX 919.1K
- Earning Date
- VWAV 11-26-2025
- BDTX 11-05-2025
- Dividend Yield
- VWAV N/A
- BDTX N/A
- EPS Growth
- VWAV N/A
- BDTX N/A
- EPS
- VWAV N/A
- BDTX 0.25
- Revenue
- VWAV N/A
- BDTX $70,000,000.00
- Revenue This Year
- VWAV N/A
- BDTX N/A
- Revenue Next Year
- VWAV N/A
- BDTX N/A
- P/E Ratio
- VWAV N/A
- BDTX $15.54
- Revenue Growth
- VWAV N/A
- BDTX N/A
- 52 Week Low
- VWAV $2.06
- BDTX $1.20
- 52 Week High
- VWAV $14.05
- BDTX $4.45
- Technical
- Relative Strength Index (RSI)
- VWAV N/A
- BDTX 53.46
- Support Level
- VWAV N/A
- BDTX $3.67
- Resistance Level
- VWAV N/A
- BDTX $4.45
- Average True Range (ATR)
- VWAV 0.00
- BDTX 0.28
- MACD
- VWAV 0.00
- BDTX -0.05
- Stochastic Oscillator
- VWAV 0.00
- BDTX 28.21
About VWAV VisionWave Holdings Inc. Common Stock
VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.